Valderrama, Jaime A.; Gonzalez, M. Florencia; Torres, Cristian, Heterocycles, 2003, vol. 60, # 10, p. 2343 - 2348
作者:Valderrama, Jaime A.、Gonzalez, M. Florencia、Torres, Cristian
DOI:——
日期:——
Extracts of Cranberry and Methods of Using Thereof
申请人:Alberte Randall S.
公开号:US20100028469A1
公开(公告)日:2010-02-04
The present disclosure relates in part to extracts of cranberry (
Vaccinium macrocarpon
) comprising an enriched amount of certain compounds having anti-infective activity, e.g. antibacterial and/or antifungal activity, e.g. activity against
C. albicans
. Another aspect of the disclosure relates to combined cranberry and cinnamon extracts. In certain embodiments, these combined extracts have been optimized to control urinary tract infections caused by
E. coli, S. aureus
and
C. albicans
. Certain embodiments of the extract are enriched in bioactive compounds that have been shown to inhibit
C. albicans
adhesion and/or biofilm formation and its growth in vitro. In another aspect of the disclosure, the extracts are enriched in bioactives derived from cranberry and cinnamon that have been shown to inhibit the attachment and the growth of common urinary tract pathogens like
E. coli, S. aureus
and
C. albicans.
ANTI-CANCER LEAD MOLECULE
申请人:KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
公开号:US20140107196A1
公开(公告)日:2014-04-17
Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER
申请人:KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
公开号:US20180049997A1
公开(公告)日:2018-02-22
In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.